Clinical Trials Logo

Metastatic Pancreatic Cancer clinical trials

View clinical trials related to Metastatic Pancreatic Cancer.

Filter by:

NCT ID: NCT03281382 Completed - Clinical trials for Metastatic Pancreatic Cancer

Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer

Start date: July 1, 2017
Phase: Phase 1
Study type: Interventional

This phase 1 trial will investigate the toxicity of combining interleukin 12 gene therapy with standard chemotherapy in metastatic pancreatic cancer.

NCT ID: NCT03261947 Completed - Colorectal Cancer Clinical Trials

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

Start date: October 25, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of TAK-931 in participants with metastatic pancreatic cancer, colorectal cancer (CRC), squamous esophageal cancer (sqEC), and squamous non-small-cell lung cancer (sqNSCLC).

NCT ID: NCT03250273 Completed - Pancreatic Cancer Clinical Trials

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Start date: November 6, 2017
Phase: Phase 2
Study type: Interventional

The proposed study is an open-label, two-arm study of entinostat plus nivolumab in patients with unresectable or metastatic cholangiocarcinoma (CCA) or pancreatic ductal adenocarcinoma (PDAC).

NCT ID: NCT03189914 Completed - Clinical trials for Metastatic Pancreatic Cancer

RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

Start date: October 2, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. After completion of the Phase 1 portion, a Phase 2a study will be conducted using a 2 stage, open-label design, of RX 3117 and Abraxane® in combination to treat subjects with metastatic pancreatic cancer as first line therapy.

NCT ID: NCT03168139 Completed - Clinical trials for Metastatic Colorectal Cancer

Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer

Keynote-559
Start date: April 18, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to show that the type, number and/or distribution of tumor metastases infiltrating immune cells such as cytotoxic T cells and/or the cytokine signature in the tumor metastases can be modulated by treatment with olaptesed pegol and to explore safety, tolerability and efficacy of olaptesed pegol in combination with pembrolizumab as a basis for subsequent studies in combination with immunotherapies, in particular checkpoint inhibitors.

NCT ID: NCT03086369 Completed - Clinical trials for Metastatic Pancreatic Cancer

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

Start date: June 22, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.

NCT ID: NCT02983500 Completed - Clinical trials for Metastatic Pancreatic Cancer

Patient Reported Outcomes Registry in Patient With Cancer Cachexia

PROXie
Start date: August 28, 2016
Phase:
Study type: Observational

Evaluation of patient reported outcomes (PRO) with tumor cachexia in a real life setting.

NCT ID: NCT02975141 Active, not recruiting - Clinical trials for Metastatic Pancreatic Cancer

Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer

AFFECT
Start date: September 2016
Phase: Phase 1
Study type: Interventional

This study sets out to determine the maximum tolerated dose (MTD) of afatinib in combination with gemcitabine/nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. The identified MTD will serve as recommended phase II dose (RP2D).

NCT ID: NCT02967770 Withdrawn - Clinical trials for Metastatic Pancreatic Cancer

Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer

PanCAN
Start date: November 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether molecularly tailored therapy can improve the efficacy of treatment when compared to standard chemotherapy combinations for patients with metastatic pancreatic cancer receiving their second line of therapy for metastatic disease.

NCT ID: NCT02921646 Terminated - Clinical trials for Metastatic Pancreatic Cancer

Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients Suffering From Pancreas Cancer

EnergiePancrea
Start date: July 10, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether evolution of resting energetic expenditure is a predictive marker of tumoral response for patients suffering from metastatic pancreatic cancer and treated with 1st line of chemotherapy.